Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Lymphoma in the Orbit

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2011 by University of Zurich.
Recruitment status was:  Enrolling by invitation
Information provided by (Responsible Party):
University of Zurich Identifier:
First received: February 23, 2011
Last updated: November 3, 2011
Last verified: November 2011

Imaging techniques have considerably improved over the last decades and ocular adnexal lymphomas (OALs) nowadays can be detected. As major advances in immunophenotyping and molecular diagnostics in histology have been achieved offering an accurate diagnosis, the investigators would like to introduce that surgical biopsy of an orbital lymphoma becomes crucial for the possibility of a correct diagnosis and proper treatment. As radiotherapy accomplished great preciseness as well and OALs respond excellently to radiation, this therapy should be the treatment of choice in local defined lymphomas instead of blind treatment with steroids. Radiation results in great local control rates of 85% to 100%

  • Trial with surgical intervention

Condition Intervention Phase
Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma
Procedure: Lymphoma-Biopsy
Phase 4

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective

Resource links provided by NLM:

Further study details as provided by University of Zurich:

Estimated Enrollment: 50
Study Start Date: February 2011
Estimated Study Completion Date: May 2012
Intervention Details:
    Procedure: Lymphoma-Biopsy
    Patients after biopsy of orbital lymphoma

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patient, who underwent biopsy of an ocular adnexal lymphoma between 01/2006 and 12/2010 at the University Hospital Zurich, Division of Ophthalmology

Inclusion criteria: - both genders

  • >17 years of age
  • underwent biopsy of an ocular adnexal lymphoma between 01/2006 and 12/2010 at the University Hospital Zurich, Division of Ophthalmology
  • diagnosis histologically proven

Exclusion criteria:

  • less than 18 years of age
  • patient underwent no MRI before surgery (biopsy)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01302912

University Hospital Zurich, Ophthalmic Clinic
Zurich, ZH, Switzerland, 8091
Sponsors and Collaborators
University of Zurich
Principal Investigator: Karla Chaloupka, MD University Hospital Zurich, Ophtalmic Clinic
  More Information

Responsible Party: University of Zurich Identifier: NCT01302912     History of Changes
Other Study ID Numbers: USZ-OALs-Register
Study First Received: February 23, 2011
Last Updated: November 3, 2011

Keywords provided by University of Zurich:
ocular adnexal lymphomas

Additional relevant MeSH terms:
Lymphoma, B-Cell, Marginal Zone
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, B-Cell
Lymphoma, Non-Hodgkin processed this record on May 25, 2017